NZ572893A - Myxoma virus mutants for cancer treatment - Google Patents
Myxoma virus mutants for cancer treatmentInfo
- Publication number
- NZ572893A NZ572893A NZ572893A NZ57289307A NZ572893A NZ 572893 A NZ572893 A NZ 572893A NZ 572893 A NZ572893 A NZ 572893A NZ 57289307 A NZ57289307 A NZ 57289307A NZ 572893 A NZ572893 A NZ 572893A
- Authority
- NZ
- New Zealand
- Prior art keywords
- myxoma virus
- cell
- activity
- group
- cancer
- Prior art date
Links
- 241000700562 Myxoma virus Species 0.000 title claims abstract description 60
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 32
- 201000011510 cancer Diseases 0.000 title claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 102220361483 c.31A>T Human genes 0.000 claims abstract description 11
- 230000002950 deficient Effects 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 40
- 206010018338 Glioma Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 208000032612 Glial tumor Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 12
- 230000014509 gene expression Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000010076 replication Effects 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 101150061325 mv gene Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 241001529936 Murinae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80364006P | 2006-06-01 | 2006-06-01 | |
| PCT/US2007/070219 WO2007143548A2 (en) | 2006-06-01 | 2007-06-01 | Myxoma virus mutants for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ572893A true NZ572893A (en) | 2011-06-30 |
Family
ID=38802246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ572893A NZ572893A (en) | 2006-06-01 | 2007-06-01 | Myxoma virus mutants for cancer treatment |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8512713B2 (https=) |
| EP (3) | EP2457584B1 (https=) |
| JP (4) | JP2009538935A (https=) |
| KR (1) | KR20090014364A (https=) |
| CN (1) | CN101460194B (https=) |
| AU (1) | AU2007256754B2 (https=) |
| CA (2) | CA2652228C (https=) |
| IL (1) | IL195297A (https=) |
| MX (1) | MX2008015265A (https=) |
| NZ (1) | NZ572893A (https=) |
| WO (1) | WO2007143548A2 (https=) |
| ZA (1) | ZA200809769B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008015265A (es) | 2006-06-01 | 2008-12-12 | Robarts Res Inst | Mutates del virus de mixoma para tratamiento del cancer. |
| FR2946536B1 (fr) * | 2009-06-11 | 2011-07-29 | Agronomique Inst Nat Rech | Utilisation d'une souche attenuee de myxoma virus comme oncolytique |
| WO2019227022A1 (en) | 2018-05-25 | 2019-11-28 | Bioventures, Llc | Myxoma virus compositions and methods of use |
| WO2020051248A1 (en) * | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
| WO2020106880A1 (en) | 2018-11-20 | 2020-05-28 | Bioventures, Llc | Cells for the production of viruses and methods of using the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135507A0 (en) | 1997-10-09 | 2001-05-20 | Pro Virus Inc | Treatment of neoplasms with viruses |
| ES2153284B1 (es) | 1998-06-10 | 2001-09-01 | Fundacion Para El Estudio Y De | Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos. |
| JP2003530301A (ja) | 1999-04-15 | 2003-10-14 | ウェルスタット バイオロジクス コーポレイション | ウイルスを用いた新生物の処置 |
| AU6175000A (en) | 1999-07-12 | 2001-01-30 | Viron Therapeutics, Inc. | Novel myxoma genes for immune modulation |
| WO2001087324A1 (en) | 2000-05-17 | 2001-11-22 | Viron Therapeutics, Inc. | Compositions and methods for promoting immunosuppression |
| PT1370668E (pt) * | 2001-03-08 | 2006-06-30 | Akzo Nobel Nv | Vacinas de vector baseadas em leporipox |
| MXPA05009526A (es) | 2003-03-07 | 2005-12-15 | Robarts Res Inst | Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica. |
| NZ550430A (en) | 2004-04-27 | 2009-06-26 | Wellstat Biologics Corp | Cancer treatment using viruses and camptothecins |
| AU2006222500B2 (en) | 2005-03-07 | 2011-09-01 | Robarts Research Institute | Use of a combination of Myxoma virus and rapamycin for therapeutic treatment |
| WO2007143545A2 (en) | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Tnf signaling in myxoma virus treatments |
| MX2008015265A (es) | 2006-06-01 | 2008-12-12 | Robarts Res Inst | Mutates del virus de mixoma para tratamiento del cancer. |
| WO2007147118A1 (en) | 2006-06-16 | 2007-12-21 | Robarts Research Institute | Infection of cells with myxoma virus requires akt activation |
-
2007
- 2007-06-01 MX MX2008015265A patent/MX2008015265A/es active IP Right Grant
- 2007-06-01 EP EP11184754.7A patent/EP2457584B1/en not_active Not-in-force
- 2007-06-01 JP JP2009513472A patent/JP2009538935A/ja not_active Withdrawn
- 2007-06-01 WO PCT/US2007/070219 patent/WO2007143548A2/en not_active Ceased
- 2007-06-01 US US12/301,961 patent/US8512713B2/en not_active Expired - Fee Related
- 2007-06-01 CA CA2652228A patent/CA2652228C/en not_active Expired - Fee Related
- 2007-06-01 CN CN2007800202887A patent/CN101460194B/zh not_active Expired - Fee Related
- 2007-06-01 CA CA2951453A patent/CA2951453A1/en not_active Abandoned
- 2007-06-01 KR KR1020087029274A patent/KR20090014364A/ko not_active Ceased
- 2007-06-01 AU AU2007256754A patent/AU2007256754B2/en not_active Ceased
- 2007-06-01 NZ NZ572893A patent/NZ572893A/en not_active IP Right Cessation
- 2007-06-01 EP EP17182211.7A patent/EP3254694A1/en not_active Withdrawn
- 2007-06-01 EP EP07798014A patent/EP2021023A4/en not_active Withdrawn
-
2008
- 2008-11-13 ZA ZA200809769A patent/ZA200809769B/xx unknown
- 2008-11-13 IL IL195297A patent/IL195297A/en active IP Right Grant
-
2013
- 2013-03-01 JP JP2013040387A patent/JP5665899B2/ja not_active Expired - Fee Related
- 2013-08-19 US US13/969,853 patent/US20130336930A1/en not_active Abandoned
-
2014
- 2014-12-09 JP JP2014248831A patent/JP2015044878A/ja active Pending
-
2016
- 2016-01-21 US US15/002,971 patent/US9980994B2/en active Active
- 2016-10-06 JP JP2016197808A patent/JP2017008105A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090014364A (ko) | 2009-02-10 |
| AU2007256754B2 (en) | 2012-11-29 |
| MX2008015265A (es) | 2008-12-12 |
| JP2017008105A (ja) | 2017-01-12 |
| EP3254694A1 (en) | 2017-12-13 |
| CA2951453A1 (en) | 2007-12-13 |
| CA2652228A1 (en) | 2007-12-13 |
| WO2007143548A3 (en) | 2008-09-25 |
| JP2015044878A (ja) | 2015-03-12 |
| WO2007143548A2 (en) | 2007-12-13 |
| IL195297A0 (en) | 2009-08-03 |
| EP2457584B1 (en) | 2017-08-09 |
| EP2021023A2 (en) | 2009-02-11 |
| EP2457584A1 (en) | 2012-05-30 |
| US8512713B2 (en) | 2013-08-20 |
| EP2021023A4 (en) | 2010-08-11 |
| CA2652228C (en) | 2017-07-11 |
| JP2009538935A (ja) | 2009-11-12 |
| US20110158945A1 (en) | 2011-06-30 |
| US20160136212A1 (en) | 2016-05-19 |
| JP5665899B2 (ja) | 2015-02-04 |
| ZA200809769B (en) | 2009-07-29 |
| US9980994B2 (en) | 2018-05-29 |
| CN101460194B (zh) | 2013-08-14 |
| US20130336930A1 (en) | 2013-12-19 |
| CN101460194A (zh) | 2009-06-17 |
| JP2013100370A (ja) | 2013-05-23 |
| AU2007256754A1 (en) | 2007-12-13 |
| IL195297A (en) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hirsch et al. | Macrophages and age-dependent resistance to herpes simplex virus in mice | |
| US9980994B2 (en) | Myxoma virus mutants for cancer treatment | |
| Sampath et al. | Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects | |
| WO2008140621A2 (en) | Transgenic oncolytic viruses and uses thereof | |
| US20220339220A1 (en) | Therapeutic agents comprising oncolytic vaccinia viruses and nk cells, and uses thereof for drugs for treatment of tumors and/or cancers | |
| US20130171106A1 (en) | Use of a combination of myxoma virus and rapamycin for therapeutic treatment | |
| AU2980000A (en) | Treatment of tumors with genetically engineered herpes virus | |
| Gridley et al. | Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. | |
| Wodarz | Computational approaches to study oncolytic virus therapy: insights and challenges | |
| HK1247113A1 (en) | Myxoma virus mutants for cancer treatment | |
| HK1170951A (en) | Myxoma virus mutants for cancer treatment | |
| US8613915B2 (en) | Attenuated strain of myxoma virus for use as an oncolytic drug | |
| CN116870014B (zh) | 贝母甲素在制备溶瘤病毒抗肿瘤增效剂中的应用以及包含贝母甲素的组合物 | |
| Ding et al. | Evaluation of tumor specificity and immunity of thymidine kinase-deleted vaccinia virus guang9 strain | |
| Lin et al. | Antagonistic action of retinoic acid against teleocidin and 12-O-tetradecanoyl-phorbol-13-acetate on activation of Epstein-Barr virus genomes | |
| Price et al. | Oncolysis by an HSV-1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma | |
| HK40011177A (en) | Therapeutic agent comprising oncolytic viruses and nk cells and application thereof in drugs for treating tumors and/or cancer | |
| HK1163175B (en) | Use of a myxoma virus that does not express functional m135r for therapeutic treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 JUN 2017 BY CPA GLOBAL Effective date: 20140417 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 JUN 2018 BY CPA GLOBAL Effective date: 20170421 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 JUN 2019 BY MURGITROYD + CO Effective date: 20180601 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 JUN 2020 BY MARTIN HUNTER Effective date: 20190531 |
|
| LAPS | Patent lapsed |